BNP Paribas

BNP Paribas is set to fill the spot left by the recent departure of Vikram Gandhi from the bank’s hybrid capital DCM team.

Cosmetics packager HCP Global has postponed its US targeted syndication for $380m, with bankers attributing the decision to a summer lull and a tough US market. A new timeline for the loan was being worked out, said bankers close to the deal.

Luxembourg, which is gearing up to sell the first euro denominated sovereign sukuk, is set to meet investors in Asia, Europe and the Middle East at the end of September. It has hired a pair of banks to lead the project.

Huvepharma, the Bulgarian animal drugs firm, has tightened pricing on its €180m six year term loan ‘B’, in a move that goes against the trend of investor pushback in the leveraged loan market.

Huvepharma - Orion Engineered Carbons - Delek Group - Emsland – Stärke

Two subsidiaries of Materis, the French, Wendel-owned building materials firm, increased margins on €432m of term loan ‘B’s as part of a refinancing, in the first signs of successful push-back from investors after weeks of borrower-friendly terms on new issues.

BNP Paribas has appointed Paul Yang as the regional head for Greater China as well as country head for China, in addition to his current responsibilities as country head for Hong Kong and CEO of BNP Paribas’ Hong Kong Branch.

Shanghai Electric Group (SEG) brought out its debut international deal on Thursday, with the local government owned equipment manufacturer offering a Reg S five year bond.

The Asian arm of Louis Dreyfus Commodities has closed syndication of its three year revolver at $500m, higher than its launch size of $300m, with the borrower’s relationship banks coming into the deal.

Cosmetics packager HCP Global is targeting a US syndication for a $380m financing, banking on a strong reception from a market that is happy to invest in cov-lite deals. The facility is split into three and has a trio of banks at the top level.

Export Import Bank of Korea (Kexim) raised $1bn with a dual tranche bond on Tuesday, pricing through its curve for the five year tranche. But even though the issuer went out with a SEC-registered deal, the bulk of the demand still came from Asian accounts.

Bulgarian animal drugs firm Huvepharma is due to close its €275m acquisition loan by the end of Wednesday, with pricing expected to tighten on the deal.